MERCK & COMPANY

Merck & Company: Evaluating a Drug Licensing Opportunity

Executive Summary

For the past 15 years, LAB Pharmaceuticals focus in developing compounds for the treatment of neurological disorders and has been in business. The company has developed a new drug called “Devanrik” for the treatment of depression, with the possibility to also curb hunger resulting in weight loss. Furthermore, there is also a prospect that this drug can be effective in dual treatment of both these symptoms at the same time.

Devanrik is in pre-clinical development and ready to enter the three phase clinical approval process, however due to financial constraints and in ...